Down regulation of MDM2 has been recognized as a potential mechanism for cancer therapy [15,16] because down-regulation of MDM2 in tumors exhibiting MDM2 over-expression should induce p53 stability and thus sensitization to DNA-damaging treatments via p53-dependent pathways [17-20]. This evidence concerns the gene TP53 and cancer.